Welcome to our dedicated page for Medicus Pharma SEC filings (Ticker: MDCX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Medicus Pharma Ltd. (NASDAQ: MDCX) SEC filings page on Stock Titan provides direct access to the company’s U.S. regulatory disclosures, including registration statements, current reports and financing-related documents. Medicus is an Ontario-incorporated biotech and life sciences company focused on SkinJect™, a doxorubicin microneedle array for basal cell carcinoma, and Teverelix, a long-acting GnRH antagonist for prostate and urologic indications.
Key filing types for MDCX include registration statements on Form S-1, which describe offerings and resale registrations tied to standby equity purchase agreements, warrant exercises and acquisition-related consideration shares. These S-1 filings outline the company’s business, risk factors, pipeline programs and capital structure in detail. Investors can review sections covering the SkinJect™ and Teverelix clinical programs, as well as the terms of equity facilities with counterparties such as YA II PN, Ltd. (Yorkville) and Armistice Capital Master Fund Ltd.
Current reports on Form 8-K document material events such as the acquisition of Antev Limited, warrant inducement agreements, new debenture financings, non-binding memoranda of understanding, and updates on clinical and regulatory milestones. For example, 8-K filings describe the Antev transaction that added Teverelix to the pipeline, the terms of a debenture issued to Yorkville, and inducement arrangements for the exercise of outstanding warrants.
Through this page, users can also monitor unregistered sales of equity securities disclosed under Item 3.02 of Form 8-K, which provide insight into how Medicus funds its clinical development activities. While insider Form 4 reports are not summarized in the provided data, Stock Titan’s platform is designed to surface such ownership changes when available.
How Stock Titan helps
Stock Titan enhances these filings with AI-powered summaries that explain complex documents in plain language, highlight key terms in S-1 and 8-K filings, and point out items relevant to Medicus’s SkinJect™ and Teverelix programs. Real-time EDGAR updates mean new MDCX filings appear quickly, and investors can use this page to track registration statements, financing terms and other regulatory disclosures without reading every page of each filing.
Medicus Pharma Ltd. registers 1,115,500 common shares issuable upon the exercise of warrants, as set forth in Prospectus Supplement No. 22 dated March 6, 2026. The supplement attaches a Current Report on Form 8-K and updates the April 10, 2025 prospectus.
The supplement restates the Public Warrants' exercise price $4.64 and expiration date November 15, 2029, and notes last reported Nasdaq prices on March 5, 2026 of $0.68 (common share) and $1.00 (Public Warrant). The Form 8-K discloses prior unregistered sales under a SEPA to YA II PN, Ltd. totaling 4,471,038 common shares for aggregate consideration of $3,846,910, and that part of those proceeds prepaid a Yorkville debenture.
Medicus Pharma Ltd. files a prospectus supplement registering up to 1,397,184 common shares and amends the Prospectus dated November 14, 2025 to incorporate its Form 8-K dated March 6, 2026. The supplement notes the company completed multiple unregistered sales to Yorkville under a Standby Equity Purchase Agreement, totaling $3,846,910 for 4,471,038 common shares as detailed in the attached table.
Medicus Pharma Ltd. registers 2,260,000 common shares issuable upon the exercise of public warrants under a prospectus supplement dated March 6, 2026. This supplement amends the May 29, 2025 prospectus and incorporates a Form 8-K filed March 6, 2026.
The Form 8-K discloses prior sales under a Standby Equity Purchase Agreement totaling 4,471,038 common shares for aggregate consideration of $3,846,910 (sales dated December 19, 2025 through March 6, 2026). The supplement notes the public warrants have an exercise price of $4.64 and expire on November 15, 2029; market prices quoted were $0.68 per common share and $1.00 per Public Warrant as of March 5, 2026.
Medicus Pharma Ltd. files a prospectus supplement registering up to 7,500,000 common shares and attaches a Form 8-K reporting equity financings under a Standby Equity Purchase Agreement.
The Form 8-K lists completed SEPA sales totaling 4,471,038 common shares for aggregate consideration of $3,846,910, and states Yorkville may purchase additional shares "subject to the satisfaction or waiver of the conditions and limitations set forth in the SEPA". The company notes its Nasdaq last sale price was $0.68.
Medicus Pharma Ltd. reported that it sold a total of 4,471,038 common shares to YA II PN, Ltd. (Yorkville) under a previously disclosed Standby Equity Purchase Agreement. These unregistered sales, completed between December 19, 2025 and March 6, 2026, generated approximate aggregate consideration of $3,846,910.
The company has used part of the net proceeds to prepay a portion of an outstanding debenture held by Yorkville, reducing that obligation. The shares were issued in private transactions relying on the Section 4(a)(2) exemption from registration, and Yorkville may resell them under an effective registration statement while Medicus may request additional share purchases under the SEPA, subject to its conditions and limitations.
Medicus Pharma Ltd. has filed a resale registration covering up to 4,020,000 common shares issuable on exercise of existing Private Warrants held by Armistice Capital Master Fund Ltd. Each warrant is immediately exercisable for one common share at an exercise price of $2.00 and expires on June 5, 2031.
The company is not selling shares in this registration and will not receive proceeds from resales by the selling shareholder, though it may receive up to $8,040,000 if the warrants are exercised for cash. Common shares trade on Nasdaq under “MDCX,” and the company qualifies as an emerging growth and smaller reporting company.
Medicus Pharma Ltd. granted its Chief Operating Officer, Andrew A. Smith, a stock option award covering 50,000 common shares on December 16, 2025. The options carry an exercise price of $1.8 per share and are reported as directly owned.
The option is scheduled to vest quarterly in four equal installments over one year, giving Smith increasing rights to purchase shares over that period. Any unexercised portion expires on December 16, 2030, aligning the executive’s potential equity ownership with the company’s longer-term performance.
Medicus Pharma Ltd. reported an insider equity award involving a company director. On December 16, 2025, the director received a stock option grant covering 25,000 common shares with an exercise price of $1.8 per share. The option is scheduled to vest quarterly in four equal installments over one year, giving the recipient rights to portions of the award every three months during that period. The option expires on December 16, 2030, and following this grant the director beneficially owns 25,000 derivative securities directly.
Medicus Pharma Ltd. director Ajay Raju reported receiving a new stock option grant. On December 16, 2025, he was granted an option to purchase 25,000 Common Shares of Medicus Pharma at an exercise price of $1.80 per share. The option is scheduled to vest quarterly in four equal installments over one year, meaning the right to purchase the shares will become available in stages rather than all at once.
The option expires on December 16, 2030, giving the director a five-year window from the grant date to exercise once vested. Following this grant, Ajay Raju beneficially owns 25,000 derivative securities in the form of this stock option, held directly.